Navigation Links
Mayo Genomic Discovery: Protecting Kidney Function During Heart Failure
Date:6/15/2009

ROCHESTER, Minn., June 15 /PRNewswire-USNewswire/ -- Mayo Clinic cardiology researchers have found a peptide that helps preserve and improve kidney function during heart failure, without affecting blood pressure. Earlier variations of this peptide caused blood pressure to drop limiting the potential benefits to the kidneys. The findings appear in the current Proceedings of the National Academy of Sciences.

"Heart failure itself and some of the approaches used to treat it can have detrimental effects on the kidneys," says Mayo cardiologist and lead researcher Robert Simari, M.D. "Our hope is that this compound will help protect kidney function while you're being treated, and possibly shorten your hospital stay and keep you out of the hospital."

This new peptide (a unique link of amino acids) has been tested in the laboratory and in animal models and is expected to move into clinical trials next year.

"One of the biggest additional concerns for patients with heart failure is the health of their kidneys," says Dr. Simari. "The extreme case is that it can lead to the kidneys shutting down completely." Nearly 5 million Americans are living with heart failure, a condition where the heart can't pump enough blood to meet the body's needs. Symptoms include shortness of breath, exercise intolerance and fluid retention. All can occur when heart function is impaired.

Seven Years of Research

The mapping of the human genome (2000-2003) revealed a gene that produces a protein called BNP (B-type natriuretic peptide). BNP was not only useful in diagnosing heart problems, it also proved therapeutic in treating heart failure. Unfortunately, says Dr. Simari, it had limited use because many heart failure patients experience low blood pressure and BNP lowered it further.

The Mayo investigators discovered an alternative splicing (AS) of BNP in messenger RNA (produced by the same gene). When they shortened the amino acid sequence of ASBNP for testing, they found that it had the same therapeutic benefits as BNP, but without the side effects to blood pressure. Positive impacts include increasing the kidney filtration rate, suppressing harmful protein production, and keeping water and salt flowing from the body. Potentially, this new drug would be given by IV to patients who are being treated in the hospital.

"There's an important reduction of kidney function every time one of these acute heart failure episodes happens," says Dr. Simari. "And by stopping one or more of those decrements, we hope there will be an overall improvement in long-term maintenance of kidney function."

Others on the team include Shuchong Pan, M.D., Ph.D.; Horng Chen, M.D.; Guido Boerrigter, M.D.; Candace Lee; Laurel Kleppe; Amir Lerman, M.D.; Margaret Redfield, M.D.; John Burnett, Jr., M.D.; all from Mayo Clinic, and Deborah Dickey, Ph.D.; Jennifer Hall, Ph.D.; and Lincoln Potter, Ph.D., all from the University of Minnesota. The research was funded by Mayo Clinic, the National Institutes of Health, and Anexon, Inc.

Mayo Clinic and five of the investigators associated with this research have a financial interest in the technology studied in the research. In accordance with the Bayh-Dole Act, that technology has been licensed to Anexon. Mayo Clinic and Drs. R. Simari and Dr. S. Pan have received royalties from the licensing of that technology of greater than the federal threshold for significant financial interest. Drs. J. Burnett, M. Redfield and H. Chen have received royalties less than the federal threshold for significant financial interest. In addition, Mayo Clinic holds an equity position in Anexon.

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Simari describing the research, are available on the Mayo Clinic News Blog.


'/>"/>
SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... It’s that time of year when most people have forgotten ... Athletic Association of Maryland (IAAM), Hall of Fame athlete and Garrison Forest School athletic ... , That’s why one of her first decisions when her IAAM two-year presidency began ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... and production of its newest mobility device, the StandUp Walker. Made entirely in ... design in the last 50 years. , StandUp Walker’s novel patent-pending design offers ...
(Date:2/9/2016)... New York, NY (PRWEB) , ... February 09, 2016 , ... ... announce the appointment of Dr. David Hung to the company´s Board of Directors. ... is a world class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... to expand access to affordable hearing aids , increase industry transparency, and ... in the United States. , “For the average consumer, the hearing aid industry ...
(Date:2/9/2016)... ... 09, 2016 , ... Sir Grout, the leading hard surface ... announce that many of their franchises have received the Super Service Award from ... franchises received customer recognition through positive reviews and testimonials, as well as evaluations ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 9, 2016  Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... fiscal 2016 first quarter ended December 31, 2015. ... 2016 First Quarter Highlights , Revenue of $36.5 ... of 2015 , Domestic Radiation Measurement services revenues increased ...
(Date:2/9/2016)... , Feb. 9, 2016  Jazz Pharmaceuticals plc ... report its 2015 fourth quarter and full year financial ... of the financial markets.  Company management will host a ... p.m. EST/9:30 p.m. GMT to discuss fourth quarter and ... and financial update and guidance for 2016 financial results. ...
(Date:2/9/2016)... Amarantus BioScience Holdings, Inc. ... for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference ... New York City . The Company,s presentation ... 12:30 pm by Gerald E. Commissiong , President ...
Breaking Medicine Technology: